Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Informed consent.

• Outpatient.

• Male or non-pregnant/non-lactating female.

• Aged 18-55.

• Diagnosis of asthma.

• Pre-bronchodilatory FEV1 > 75% predicted.

• Using inhaled short-acting beta-2-agonists (SABA) with no inhaled corticosteroids.

• Judged capable of withholding SABA for at least 6 hours prior to visits.

• Reversibility of >12% and 200mL or PC20 of <8mg/mL.

• Demonstration of atopy

Exclusion Criteria:

• History of life-threatening asthma.

• Use of proscribed asthma medications.

• Use of anti-histamines or potent inhibitors of CYP3A4.

• Respiratory tract infection.

• Asthma exacerbation with 4 weeks of Visit 1.

• Subjects with exercise induced asthma only.

• Concurrent respiratory disease.

• Other clinically significant, uncontrolled condition or disease.

• Use of any investigational drug within 30 days.

• Allergic to beta-2-agonists, inhaled corticosteroids or excipients.

• Positive pregnancy test.

• Using immunosuppressive medications.

• Milk protein allergy.

• Factors likely to interfere with attendance.

• Current smokers or ex-smokers with a history of >10 pack years.

• Affiliation wih Investigator site.

• Medications that may affect the course of asthma or interact with sympathomimetic amines.